Innovative Biologics, Biosimilars and Biobetters: Development of Biopharma Industry in Taiwan
碩士 === 國立交通大學 === 管理學院高階主管管理碩士學程 === 106 === Biologics have been gaining significant attraction in the pharmaceutical industry in last two decades. However the high cost of biologics has become an important issue in the battle concerning ever-increasing healthcare costs. In 2016 the global sales o...
Main Authors: | Wang, Ren-Hong, 王仁宏 |
---|---|
Other Authors: | Chu, Po-Young |
Format: | Others |
Language: | zh-TW |
Published: |
2018
|
Online Access: | http://ndltd.ncl.edu.tw/handle/bzb399 |
Similar Items
-
From Biologics to Biosimilars and Biobetters - Democratization of High-end Therapeutics
by: Santosh G Honavar
Published: (2021-01-01) -
843 Reproducible, MoA-reflecting reporter-based bioassays to enable drug development of biosimilars and biobetters
by: Jennifer Wilkinson, et al.
Published: (2020-11-01) -
Collaborative Innovation: The Future of BioPharma
by: Cristián Hernández-Cuevas
Published: (2007-09-01) -
Analyzing the IT architecture landscape in the biopharma Industries
by: Bhashyam, Sriram Balaji.
Published: (2019) -
What Finance Can Learn from Biopharma Industry: A Transfer of Innovation Models
by: Francesco COREA
Published: (2015-12-01)